Shots:

• The P-III MONALEESA-7 study results involves assessing of Kisqali in combination with endocrine therapy (goserelin + aromatase inhibitor/tamoxifen) vs endocrine therapy as monothx. in pre- and perimenopausal women with HR+/HER2- advanced or metastatic breast cancer
• The P-III MONALEESA-7 study resulted in improving survival rate @42mos. (70.2% vs 46.0%)- 30%/20.9% reduction in risk of death- no new safety signals were observed- presented at ASCO 2019 respectively
•  Kisqali is the CDK4/6 inhibitor- currently evaluated in P-III NATALEE study with endocrine therapy as an adjuvant treatment of HR+/HER2- early breast cancer and is approved in 75+ countries including the US & EU for the same indication

Ref: Novartis | Image:  Coroflot